E-FACED Score Calculator

Evaluates disease severity and mortality risks associated with non-cystic fibrosis bronchiectasis based on exacerbations and clinical factors.

Read more about the properties of original FACED score and its new version in the text below the tool.


Both FACED and E-FACED scores are instrumental in guiding clinical decisions and predicting mortality over both short and long-term periods post-diagnosis. The E-FACED score adds a component for exacerbations to the five dichotomized factors of the original FACED score.


The interpretation of both scores is summarized in a table indicating mild, moderate, and severe bronchiectasis based on the total points scored.

Disease severity E-FACED score FACED score
Mild bronchiectasis 0 – 3 points 0 – 2 points
Moderate bronchiectasis 4 – 6 points 3 – 4 points
Severe bronchiectasis 7 – 9 points 5 – 7 points

1

At least one severe Exacerbation in previous year

2

FEV1 % predicted

3

Age

4

Chronic colonisation by Pseudomonas aeruginosa

5

Extension

6

Dyspnoea

(modified Medical Research Council scale – mMRC)
  Embed  Print  Share 
1

FEV1 % predicted

2

Age

3

Chronic colonisation by Pseudomonas aeruginosa

4

Extension

5

Dyspnoea

(modified Medical Research Council scale – mMRC)
Print 

Send Us Your Feedback

Steps on how to print your input & results:

1. Fill in the calculator/tool with your values and/or your answer choices and press Calculate.

2. Then you can click on the Print button to open a PDF in a separate window with the inputs and results. You can further save the PDF or print it.

Please note that once you have closed the PDF you need to click on the Calculate button before you try opening it again, otherwise the input and/or results may not appear in the pdf.


 

E-FACED Score explained

E-FACED score and its predecessor FACED facilitate the assessment of morbidity and mortality of people with non-cystic fibrosis bronchiectasis through various clinical, functional, radiological and microbiological variables.

By identifying high risk patients, clinicians may be guided regarding the frequency and intensity of follow-up and the use of chronic antibiotic therapy.

The E-FACED score consists of an item regarding exacerbations and five dichotomised variables (same as those of the preceding FACED):

E – Severe Exacerbations in previous year (no = 0 points, yes = 2 points)

F – FEV1 (≥ 50% = 0 points, < 50% = 2 points)

A – Age (< 70 years = 0 points, ≥ 70 years = 2 points)

C – Chronic colonisation (no Pseudomonas = 0 points, presence of Pseudomonas = 1 point)

E – Extension (1 – 2 lobes affected = 0 points, > 2 lobes affected= 1 point)

D – Dyspnoea – modified Medical Research Council scale – mMRC (0 – 2 = 0 points, 3 – 4 = 1 point)

The table below summarizes the result interpretation for both scores:

Disease severity E-FACED score FACED score
Mild bronchiectasis 0 – 3 points 0 – 2 points
Moderate bronchiectasis 4 – 6 points 3 – 4 points
Severe bronchiectasis 7 – 9 points 5 – 7 points
 

About the original studies

Both FACED and E-FACED are multidimensional scores that classifies the severity of non-CF bronchiectasis according to its prognosis. They have been developed following observational multicentre studies.

The FACED score was derived based on results from a cohort of 397 subjects diagnosed with non-cystic fibrosis bronchiectasis using high-resolution computed tomography and validated on 422 subjects.

The outcome was 5-year all-cause mortality after radiological diagnosis. A logistic regression analysis was used to select the variables included in the final score.

The area under the receiver operating characteristic curve (AUC) of the final score to predict 5-year all-cause mortality was 0.87 (the greater the AUC, the better the prognostic value of the FACED score.

The division into three scoring groups differentiated bronchiectasis into three distinct mortality groups, according to the results of the Kaplan–Meier analysis: mild (4.3% mortality), moderate (24.7% mortality) and severe (55.9% mortality) bronchiectasis.

New studies are required to evaluate this score’s sensitivity to change by applying therapeutic variables in the follow-up.

The subsequent E-FACED score introduces the predictive capacity of exacerbations and mortality. The new scoring system was constructed on the basis of the 819 subjects cohort for the derivation and validation of the original FACED score, while the external validation was undertaken with six different cohorts, totalling 651 subjects, from three countries.

E-FACED presented an excellent prognostic capacity for exacerbations (areas under the receiver operating characteristic curve: 0.82 for at least two exacerbations in 1 year and 0.87 for at least one hospitalization in 1 year). This result is statistically better than that of the FACED score (0.72 and 0.78, P<0.05, respectively).

E-FACED score significantly increases the FACED capacity to predict future yearly exacerbations and maintains the same predictive capacity for all-cause and respiratory mortality.

Both FACED and E-FACED may assist clinical decision making and predict all-cause mortality, not only in the long term, but also for short-term follow-up (yearly from the first to the fifth year after diagnosis).

The two scores’ sensitivity to change after therapeutic interventions require future evaluation.

A close tool is the Bronchiectasis Severity Index (BSI), which was found to provide a similar assessment of disease severity.

 

References

Original references

Martinez-Garcia MA, Athanazio RA, Girón R, Máiz-Carro L, de la Rosa D, Olveira C, de Gracia J, Vendrell M, Prados-Sánchez C, Gramblicka G, Corso Pereira M, Lundgren FL, Fernandes De Figueiredo M, Arancibia F, Rached SZ. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis. 2017 Jan 18;12:275-284

Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón RM, Máiz Carro L, de la Rosa Carrillo D, Olveira C (2014) .Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. May;43(5):1357-67.

Other references

de la Rosa Carrillo D, Athanazio R, Girón Moreno RM, Máiz Carro L, Olveira C, de Gracia J, Vendrell M, Prados Sánchez C, Gramblicka G, Corso Pereira M, Lundgren F, Fernandes De Figueiredo M, Arancibia F, Rached S, Martínez-Garcia MA. The annual prognostic ability of FACED and E-FACED scores to predict mortality in patients with bronchiectasis. ERJ Open Res. 2018 Mar 6;4(1):00139-2017.

Minov J, Karadzinska-Bislimovska J, Vasilevska K, Stoleski S, Mijakoski D. Assessment of the Non-Cystic Fibrosis Bronchiectasis Severity: The FACED Score vs the Bronchiectasis Severity Index. Open Respir Med J. 2015 Mar 31;9:46-51.


Specialty: Pulmonology

System: Respiratory

Objective: Stratification

Type: Score

No. Of Criteria: 5

Year Of Study: 2014

Abbreviation: FACED

Article By: Denise Nedea

Published On: March 19, 2024 · 12:00 AM

Last Checked: March 19, 2024

Next Review: March 19, 2029